VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the cholesterol and recurrent events (CARE) trial

Circulation

Volumn 102, Issue 16, 2000, Pages 1886-1892

  Sacks, Frank M ^a,b   Alaupovic, Petar ^c   Moye, Lemuel A ^d   Cole, Thomas G ^e   Sussex, Bruce ^f   Stampfer, Meir J ^a,b   Pfeffer, Marc A ^b   Braunwald, Eugene ^b  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

^d UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^e WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

Author keywords

Apolipoproteins; Cholesterol; Coronary disease; Lipoproteins

Indexed keywords

APOLIPOPROTEIN B; APOLIPOPROTEIN C3; APOLIPOPROTEIN E; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIURETIC AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ADULT; AGED; ARTICLE; ATHEROGENESIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY RISK; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; RISK FACTOR; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0034680309     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.102.16.1886     Document Type: Article

References (27)

1. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: A meta-analysis of population-based prospective studies
2. A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction
3. Triglyceride concentration and ischemic heart disease: An 8-year follow-up in the Copenhagen Male Study
4. Cholesterol reduction and its impact on coronary artery disease and total mortality
5. High-density lipoprotein: The clinical implications of recent studies
6. Significance of apolipoproteins for structure, function, and classification of plasma lipoproteins
7. Triglyceride-rich lipoprotein remnant particles and risk of atherosclerosis
8. A mouse model with features of familial combined hyperlipidemia
9. Apolipoprotein E deficiency in mice: Gene replacement and prevention of atherosclerosis using adenovirus vectors
10. Logistic discriminant analysis of lipids and apolipoproteins in a population of coronary bypass patients and the significance of apolipoproteins C-III and E
11. Apolipoproteins C-III and E in apoB-and non-apoB-containing lipoproteins in two populations at contrasting risk for myocardial infarction: The ECTIM study
12. Prediction of angiographic change in native human coronary arteries and aortocoronary bypass grafts
13. The role of triglyceride-rich lipoprotein families in the progression of atherosclerotic lesions as determined by sequential coronary angiography from a controlled clinical trial
14. Triglyceride- and cholesterol-rich lipoproteins have a differential effect on mild/moderate and severe lesion progression as assessed by quantitative coronary angiography in a controlled trial of lovastatin
15. Plasma apolipoprotein AI, AII, B, E and CIII containing particles in men with premature coronary artery disease
16. Enrichment with apolipoprotein E characterizes postprandial TG-rich lipoproteins in patients with non-insulin-dependent diabetes mellitus and coronary artery disease: A preliminary report
17. IDL, VLDL, chylomicrons and atherosclerosis
18. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
19. A comprehensive evaluation of the heparin-manganese precipitation procedure for estimating high density lipoprotein cholesterol
20. Quantitative determination of human apolipoprotein CIII by electroimmunoassay
21. Determination of human apolipoprotein E by electroimmunoassay
22. Chylomicronemia due to apolipoprotein CIII overexpression in apolipoprotein E-null mice: Apolipoprotein CIII-induced hypertriglyceridemia is not mediated by effects on apolipoprotein E
23. Mechanism of hypertriglyceridemia in human apolipoprotein (apo) CIII transgenic mice
24. Effects of estrogenic oral contraceptives on the lipoprotein B particle system defined by apolipoproteins E and CIII
25. Type III hyperlipoproteinemia associated with apolipoprotein E deficiency
26. Overexpression and accumulation of apolipoprotein E as a cause of hypertriglyceridemia
27. Very low density lipoproteins stimulate cholesteryl ester formation in U937 macrophages: Heterogeneity and biologic variation among normal humans